Akari Therapeutics EBITDA vs. Price To Book
| AKTX Stock | USD 1.30 0.06 4.84% |
EBITDA | First Reported 2010-12-31 | Previous Quarter -16.8 M | Current Value -17.6 M | Quarterly Volatility 12.6 M |
For Akari Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Akari Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Akari Therapeutics PLC utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Akari Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Akari Therapeutics PLC over time as well as its relative position and ranking within its peers.
Akari |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Akari Therapeutics. If investors know Akari will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Akari Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.58) | Return On Assets (1.73) | Return On Equity (12.81) |
The market value of Akari Therapeutics PLC is measured differently than its book value, which is the value of Akari that is recorded on the company's balance sheet. Investors also form their own opinion of Akari Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Akari Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Akari Therapeutics' market value can be influenced by many factors that don't directly affect Akari Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Akari Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Akari Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Akari Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Akari Therapeutics PLC Price To Book vs. EBITDA Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Akari Therapeutics's current stock value. Our valuation model uses many indicators to compare Akari Therapeutics value to that of its competitors to determine the firm's financial worth. Akari Therapeutics PLC is rated second in ebitda category among its peers. It is rated third in price to book category among its peers . Akari Therapeutics reported EBITDA of (16.8 Million) in 2023. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Akari Therapeutics' earnings, one of the primary drivers of an investment's value.Akari Price To Book vs. EBITDA
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Akari Therapeutics |
| = | (16.8 M) |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Akari Therapeutics |
| = | 3.07 X |
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
Akari Price To Book Comparison
Akari Therapeutics is currently under evaluation in price to book category among its peers.
Akari Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Akari Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Akari Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Akari Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Akari Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 51.2 M | 53.7 M | |
| Operating Income | -16.8 M | -17.6 M | |
| Income Before Tax | -10 M | -10.5 M | |
| Total Other Income Expense Net | 6.8 M | 7.1 M | |
| Net Loss | -10 M | -10.5 M | |
| Income Tax Expense | -9.7 M | -9.2 M | |
| Net Loss | -20.4 M | -21.4 M | |
| Net Loss | -20 M | -21 M | |
| Interest Income | 41.3 K | 39.3 K | |
| Net Interest Income | 41.3 K | 70.5 K | |
| Change To Netincome | 501.4 K | 476.4 K | |
| Net Loss | (2.04) | (2.15) | |
| Income Quality | 1.64 | 1.72 | |
| Net Income Per E B T | 0.45 | 0.89 |
Akari Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Akari Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Akari Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Akari Therapeutics' important profitability drivers and their relationship over time.
Use Akari Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Akari Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Akari Therapeutics will appreciate offsetting losses from the drop in the long position's value.Akari Therapeutics Pair Trading
Akari Therapeutics PLC Pair Trading Analysis
The ability to find closely correlated positions to Akari Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Akari Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Akari Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Akari Therapeutics PLC to buy it.
The correlation of Akari Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Akari Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Akari Therapeutics PLC moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Akari Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Akari Therapeutics position
In addition to having Akari Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Soft Drinks Thematic Idea Now
Soft Drinks
Entities manufacturing and distributing non alcoholic beverages across different markets. The Soft Drinks theme has 40 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Soft Drinks Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Akari Stock Analysis
When running Akari Therapeutics' price analysis, check to measure Akari Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Akari Therapeutics is operating at the current time. Most of Akari Therapeutics' value examination focuses on studying past and present price action to predict the probability of Akari Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Akari Therapeutics' price. Additionally, you may evaluate how the addition of Akari Therapeutics to your portfolios can decrease your overall portfolio volatility.